Cognito Therapeutics said its phase 3 HOPE study of Spectris AD, an investigational, non-invasive, at-home Alzheimer's therapy that uses light and sound stimulation to engage brain activity, failed to meet its primary endpoint.
In the primary analysis population of 663 patients, the change from baseline in the integrated Alzheimer’s Disease MMSE and ADCS-ADL Rating Scale, did not differ between Spectris and sham at month 12.
However, a prespecified analysis of participants with mild Alzheimer's favored Spectris on measures of thinking and daily function. The device works by sending Cognition-designed visual and auditory stimulation designed to preserve brain structure and function.
In the mild Alzheimer's subgroup, Spectris showed nominally significant slowing of decline on CDR-SB, daily function, and instrumental activities of daily living. The difference in outcomes between participants with mild and moderate disease raises the possibility that earlier intervention may be key to clinical benefit, according to the Alzheimer's Drug Discovery Foundation (ADDF), who funded the trial through a research grant.
"While the HOPE study did not meet its primary endpoint, the signal in the mild Alzheimer's subgroup raises important questions that are worth exploring further," said Laura Nisenbaum, PhD, Interim Chief Science Officer of the ADDF, in a statement.
"Daily function is what patients and families tell us matters most, so it will be important to see whether the early signs of slower decline on that measure in people with mild Alzheimer's hold up as more data become available."
Spectris is engineered to treat all Alzheimer patients, including the estimated 40% to 65% of those who carry the APOE4 gene and are not candidates for conventional FDA-approved monoclonal antibody treatments. Nearly 75% of the current drug pipeline now focused on pathways beyond amyloid and tau, the Alzheimer's Drug Discovery Foundation noted.
"Mixed results are part of how science moves forward. For the millions of Alzheimer's patients who are not candidates for anti-amyloid therapies, or who need options beyond a single drug, these findings add important new information," said Isobel Coleman, Chief Executive Officer of the ADDF, in the release.
"This is exactly the kind of science the ADDF's venture philanthropy model is designed to support: testing innovative, high-risk ideas that others may not yet be willing to fund and generating data the field needs to know which approaches deserve further investment. Studies like this move us closer to a future where multiple therapies tailored to each patient can become the standard of care."
Cognito said it plans to engage with the FDA to review the HOPE results and discuss a potential path to authorization for Spectris AD in people with early symptomatic Alzheimer's disease.